Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies

Abstract

Rituximab treatment is associated with a high degree of ADAs, which correlates with efficacy of B-cell depletion; however, the clinical relevance of ADAs remains uncertain.